207 related articles for article (PubMed ID: 19402172)
21. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Lee EQ; Puduvalli VK; Reid JM; Kuhn JG; Lamborn KR; Cloughesy TF; Chang SM; Drappatz J; Yung WK; Gilbert MR; Robins HI; Lieberman FS; Lassman AB; McGovern RM; Xu J; Desideri S; Ye X; Ames MM; Espinoza-Delgado I; Prados MD; Wen PY
Clin Cancer Res; 2012 Nov; 18(21):6032-9. PubMed ID: 22923449
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Prados MD; Lamborn KR; Chang S; Burton E; Butowski N; Malec M; Kapadia A; Rabbitt J; Page MS; Fedoroff A; Xie D; Kelley SK
Neuro Oncol; 2006 Jan; 8(1):67-78. PubMed ID: 16443950
[TBL] [Abstract][Full Text] [Related]
24. O6-benzylguanine-mediated enhancement of chemotherapy.
Friedman HS; Keir S; Pegg AE; Houghton PJ; Colvin OM; Moschel RC; Bigner DD; Dolan ME
Mol Cancer Ther; 2002 Sep; 1(11):943-8. PubMed ID: 12481416
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Coan A; Desjardins A; Peters KB; Gururangan S; Sathornsumetee S; Rich JN; Herndon JE; Friedman HS
J Neurooncol; 2011 Dec; 105(3):621-7. PubMed ID: 21744079
[TBL] [Abstract][Full Text] [Related]
26. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
28. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
Warren KE; Aikin AA; Libucha M; Widemann BC; Fox E; Packer RJ; Balis FM
J Clin Oncol; 2005 Oct; 23(30):7646-53. PubMed ID: 16234526
[TBL] [Abstract][Full Text] [Related]
30. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
31. A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Hargrave D; Geoerger B; Frappaz D; Pietsch T; Gesner L; Cisar L; Breazna A; Dorman A; Cruz-Martinez O; Fuster JL; Rialland X; Icher C; Leblond P; Ashley D; Perilongo G; Elliott M; English M; Clausen N; Grill J
J Neurooncol; 2013 May; 113(1):127-34. PubMed ID: 23459995
[TBL] [Abstract][Full Text] [Related]
32. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Holdhoff M; Ye X; Supko JG; Nabors LB; Desai AS; Walbert T; Lesser GJ; Read WL; Lieberman FS; Lodge MA; Leal J; Fisher JD; Desideri S; Grossman SA; Wahl RL; Schiff D
Neuro Oncol; 2017 Jun; 19(6):845-852. PubMed ID: 28371832
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Reynés G; Balañá C; Gallego O; Iglesias L; Pérez P; García JL
Anticancer Drugs; 2014 Jul; 25(6):717-22. PubMed ID: 24322542
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Blakeley JO; Grossman SA; Mikkelsen T; Rosenfeld MR; Peereboom D; Nabors LB; Chi AS; Emmons G; Garcia Ribas I; Supko JG; Desideri S; Ye X
J Neurooncol; 2015 Oct; 125(1):123-31. PubMed ID: 26285766
[TBL] [Abstract][Full Text] [Related]
37. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Friedman HS; Keir ST; Houghton PJ
Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457
[TBL] [Abstract][Full Text] [Related]
38. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Chamberlain MC; Glantz MJ
J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
[TBL] [Abstract][Full Text] [Related]
39. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Gruber ML; Buster WP
Am J Clin Oncol; 2004 Feb; 27(1):33-8. PubMed ID: 14758131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
